Latest News

Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

09.12.2011

Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET

Berlin, Germany, and Seattle, WA, U.S.A.

Conference Call for Investors and Media

Dial-in number (within Germany): 

+49 69 247 501 899

Dial-in number (within U.K.):

+44 203 147 4861 

Dial-in number (within the US):

+1 212 444 0297

 

Participants are kindly requested to dial in 10 minutes prior to the start of the call.

A recording of the conference call will be provided here on our website subsequently.

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About Epigenomics

Epigenomics legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.